Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy
- 1 June 2005
- journal article
- Published by Wiley in BJU International
- Vol. 95 (9) , 1336-1343
- https://doi.org/10.1111/j.1464-410x.2005.05528.x
Abstract
To evaluate the efficacy of antitumour vaccines comprising irradiated allogeneic or autologous whole cells expressing cytosine deaminase (CD) which are first killed ex vivo by prodrug activation using 5-fluorocytosine (5-FC), as the immunogenicity of tumour cells used as irradiated vaccines depends both on antigen expression and on the mode of their death. The PA3 rat prostate cell line and MATLyLu, an androgen-insensitive subline, were grown and transfected with CD (designated PCD and MCD). In vitro drug-sensitivity was assessed in the cell lines using a viability assay, and the mode of cell death quantified by assessing apoptosis. Bax and bcl-2 expression were assessed by Western blot analysis. For in vivo experiments, male 8-10-week-old Lobund-Wistar rats were vaccinated (using vehicle in control groups) with 5 x 10(6) cells, all cells being irradiated before injection, to give groups with PA3, PCD, PCD killed with 5-FC, MatLyLu, MCD, and MCD killed with 5-FC. After 7 days all animals were given a subcutaneous tumour challenge of PA3 cells, and tumour volume measured subsequently. Immune responses were assessed in splenocytes. The efficiency of cell kill varied between the cell lines assessed, but cell death was by induced apoptosis. Single doses of vaccine were most effective in the allogeneic setting, causing significantly slower growth of syngeneic tumour challenge (P < 0.01), and 25% better survival at 50 days (P < 0.02) than irradiated untransfected cells. This was consistent with the greater proliferative response after allogeneic than autologous vaccination. The immunogenicity of irradiated tumour cells is enhanced when they are killed ex-vivo using suicide-gene therapy. This approach would be clinically applicable in terms of ease of vaccine production, safety, storage and avoidance of potential toxicities of in vivo gene transfer.Keywords
This publication has 27 references indexed in Scilit:
- Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategiesProstate Cancer and Prostatic Diseases, 2003
- Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniquesGene Therapy, 2001
- Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunityGene Therapy, 2000
- The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic CellsThe Journal of Experimental Medicine, 2000
- Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinomaGene Therapy, 2000
- The Immune Response Elicited by Mammary Adenocarcinoma Cells Transduced with Interferon-γand Cytosine Deaminase Genes Cures Lung Metastases by Parental CellsHuman Gene Therapy, 1998
- Apoptosis induced at different dose rates: implication for the shoulder region of cell survival curvesRadiotherapy and Oncology, 1994
- The lobund-wistar rat model of prostate cancerJournal of Cellular Biochemistry, 1992
- Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancersThe Prostate, 1986
- The Dunning R3327 Prostate Adenocarcinoma in the Fischer-Copenhagen F1 Rat: A Useful Model for Immunological StudiesOncology, 1977